mRNA ÇÕ¼º ¹× Á¦Á¶ ½ÃÀå ºÐ¼®°ú ¿¹Ãø(-2034³â) : À¯Çü, Á¦Ç°, ¼­ºñ½º, ±â¼ú, ¿ëµµ, ÇÁ·Î¼¼½º, ÃÖÁ¾»ç¿ëÀÚ, ÄÄÆ÷³ÍÆ®, ½ºÅ×ÀÌÁö
mRNA Synthesis and Manufacturing Market Analysis and Forecast to 2034: Type, Product, Services, Technology, Application, Process, End User, Component, Stage
»óǰÄÚµå : 1813548
¸®¼­Ä¡»ç : Global Insight Services
¹ßÇàÀÏ : 2025³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 318 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,750 £Ü 6,731,000
Single User License help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇϸç, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 5,750 £Ü 8,148,000
Site License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(±¹°¡)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,750 £Ü 9,565,000
Enterprise License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ Àü ¼¼°è ¸ðµçºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

mRNA ÇÕ¼º¡¤Á¦Á¶ ½ÃÀåÀº 2024³â 14¾ï ´Þ·¯¿¡¼­ 2034³â¿¡´Â 82¾ï ´Þ·¯·Î È®´ëÇϸç, ¾à 19.3%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. mRNA ÇÕ¼º ¹× Á¦Á¶ ½ÃÀå¿¡´Â Ä¡·á ¹× ¹é½Å¿ë ¸Þ½ÅÀú RNA »ý»êÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ ½ÃÀåÀº mRNA ±â¹Ý ¼Ö·ç¼ÇÀÇ ½Å¼ÓÇÑ °³¹ß ¹× È®À强À» °¡´ÉÇÏ°Ô ÇÏ´Â »ý¸í°øÇÐ ±â¼úÀÇ ¹ßÀü¿¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ºÐ¾ß´Â ÇÕ¼º ±â¼ú, Á¤Á¦ °øÁ¤, À¯È¿¼º°ú ¾ÈÀü¼ºÀ» º¸ÀåÇϱâ À§ÇÑ Ç°Áú°ü¸® µîÀÌ ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿Í °¨¿°º´ ´ëÀÀ °­È­°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖÀ¸¸ç, ¿¬±¸¿Í ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ°¡ Ȱ¹ßÈ÷ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù.

mRNA ÇÕ¼º ¹× Á¦Á¶ ½ÃÀåÀº »ý¸í°øÇÐ ±â¼úÀÇ ¹ßÀü°ú ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀå¿¡¼­´Â È¿À²ÀûÀ̰í È®Àå °¡´ÉÇÑ »ý»ê ¹æ½ÄÀÇ Çʿ伺À¸·Î ÀÎÇØ ÇÕ¼º ºÐ¾ß°¡ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. º¯Çü ´ºÅ¬·¹¿ÀƼµåÀÇ ÇÕ¼ºÀº mRNAÀÇ ¾ÈÁ¤¼º°ú ¹ø¿ª È¿À²À» ³ôÀÌ´Â ¿ªÇÒÀ» ÇϹǷΠƯÈ÷ ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. Á¦Á¶ ºÐ¾ß¿¡¼­´Â Àü¹®ÀûÀÎ ¼­ºñ½º¿Í Àü¹® Áö½ÄÀ» Á¦°øÇÒ ¼ö ÀÖ´Â ¼öŹÁ¦Á¶±â°ü(CMO)ÀÌ °¢±¤À» ¹Þ°í ÀÖ½À´Ï´Ù. ¹é½Å °³¹ß ºÎ¹®Àº mRNA ¹é½ÅÀÇ ¼º°ø¿¡ ÈûÀÔ¾î °¨¿°º´ ´ëÀÀÀ» À§ÇÑ mRNA ¹é½ÅÀÇ ¼º°ø¿¡ ÈûÀÔ¾î ÃÖ°í ¼öÁØÀÇ ½ÇÀûÀ» ´Þ¼ºÇϰí ÀÖ½À´Ï´Ù. Ä¡·áÁ¦´Â ƯÈ÷ Á¾¾çÇÐ ¹× Èñ±ÍÁúȯ¿¡¼­ Ç¥ÀûÄ¡·áÁ¦·ÎÀÇ ÀüȯÀ» ¹Ý¿µÇÏ¿© µÎ ¹øÂ°·Î ³ôÀº ¼º°ú¸¦ °ÅµÎ¾ú½À´Ï´Ù. ÁöÁú ³ª³ëÀÔÀÚ Àü´Þ ½Ã½ºÅÛÀÇ Çõ½Åµµ mRNA ±â¹Ý Ä¡·áÁ¦ÀÇ Àü´Þ°ú È¿´ÉÀ» Çâ»ó½ÃÄÑ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­
À¯Çü ½ÃÇè°ü³» Àü»ç mRNA, ¼ö½Ä mRNA, ºñ¼ö½Ä mRNA, ÀÚ±â ÁõÆø mRNA
Á¦Ç° mRNA ÄÁ½ºÆ®·°Æ®, mRNA ¹é½Å, mRNA Ä¡·áÁ¦, mRNA Àü´Þ ½Ã½ºÅÛ
¼­ºñ½º Ä¿½ºÅÒ mRNA ÇÕ¼º, mRNA ÃÖÀûÈ­, ºÐ¼® ¼­ºñ½º, ǰÁú°ü¸®, ±ÔÁ¦ Áö¿ø
±â¼ú ¹«¼¼Æ÷ ½Ã½ºÅÛ, È¿¼Ò ÇÕ¼º, È­ÇÐ ÇÕ¼º, ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ½Ã½ºÅÛ
¿ëµµ °¨¿°Áõ, ¾ÏÄ¡·á, À¯ÀüÀÚ Áúȯ, ½ÉÇ÷°üÁúȯ, Èñ±ÍÁúȯ
ÇÁ·Î¼¼½º ¾÷½ºÆ®¸² °øÁ¤, ´Ù¿î½ºÆ®¸² °øÁ¤, Á¦Á¦È­, Fill and Finish
ÃÖÁ¾»ç¿ëÀÚ Á¦¾àȸ»ç, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, ¿¬±¸±â°ü, Á¦Á¶ ¼öŹ ±â°ü
ÄÄÆ÷³ÍÆ® ´ºÅ¬·¹¿ÀƼµå, È¿¼Ò, ¿ÏÃæ¾×, ½Ã¾à
½ºÅ×ÀÌÁö ÀüÀÓ»ó, ÀÓ»ó, »ó¾÷

½ÃÀå ÇöȲ

mRNA ÇÕ¼º ¹× Á¦Á¶ ½ÃÀåÀº ½ÃÀå Á¡À¯À², °¡°Ý Àü·«, Á¦Ç° Çõ½Å¿¡ ÀÖÀ¸¸ç, ¿ªµ¿ÀûÀÎ º¯È­¸¦ °Þ°í ÀÖ½À´Ï´Ù. ±âÁ¸ ±â¾÷Àº ½ÃÀå ħÅõ·ÂÀ» ³ôÀ̱â À§ÇØ °æÀï·Â ÀÖ´Â °¡°Ý Ã¥Á¤¿¡ ÁýÁßÇÏ´Â ¹Ý¸é, ½Å±Ô ÁøÃâ±â¾÷Àº »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Àâ±â À§ÇØ Çõ½ÅÀûÀÎ Á¦Ç°À» Ãâ½ÃÇϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀå¿¡´Â Ä¡·á ¿ëµµ¿¡ ÁßÁ¡À» µÐ Á¦Ç° ÆÄÀÌÇÁ¶óÀÎÀÌ Ç³ºÎÇÕ´Ï´Ù. ºÏ¹Ì´Â ±â¼ú ¹ßÀü°ú R&D ÅõÀÚ Áõ°¡¿¡ ÈûÀÔ¾î ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾çÀº Àü·«Àû Á¦ÈÞ¿Í ÀÎÇÁ¶ó È®´ë·Î ÀÎÇØ ź·ÂÀ» ¹Þ°í ÀÖ½À´Ï´Ù. °æÀï ±¸µµÀÇ Æ¯Â¡Àº Moderna, BioNTech, CureVac µî ÁÖ¿ä ±â¾÷ÀÌ Àü·«Àû Á¦ÈÞ¿Í ±â¼ú·ÂÀ¸·Î ¾÷°èÀÇ º¥Ä¡¸¶Å©¸¦ ¼³Á¤Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ºÏ¹Ì¿Í À¯·´ÀÇ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â ¸Å¿ì Áß¿äÇϸç, ½ÃÀå ¿ªÇÐ ¹× ÄÄÇöóÀ̾𽺠ǥÁØ¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ½ÃÀåÀº ÇÕ¼º»ý¹°ÇÐ ¹× ¸ÂÃãÀÇ·áÀÇ ¹ßÀü¿¡ ÈûÀÔ¾î ¼ºÀåÇÒ Å¼¼¸¦ °®Ãß°í ÀÖ½À´Ï´Ù. ±×·¯³ª ±ÔÁ¦ À庮°ú ³ôÀº Á¦Á¶ ºñ¿ë µîÀÇ °úÁ¦´Â ¿©ÀüÈ÷ ³²¾ÆÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸Çϰí ÁøÇà ÁßÀÎ ±â¼ú Çõ½Å°ú Àü·«Àû ÆÄÆ®³Ê½ÊÀº ÀÌÇØ°ü°èÀڵ鿡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ:

mRNA ÇÕ¼º ¹× Á¦Á¶ ½ÃÀåÀº ¸î °¡Áö ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎÀ¸·Î ÀÎÇØ °­·ÂÇÑ ¼ºÀåÀ» ´Þ¼ºÇϰí ÀÖ½À´Ï´Ù. mRNA ±â¹Ý ¹é½Å ¹× Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â COVID-19 ¹é½ÅÀÇ ¼º°ø¿¡ ÈûÀÔÀº ÁÖ¿ä ÃËÁøÁ¦ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿ä´Â »ý»ê È¿À²¼º°ú È®À强À» ³ôÀ̱â À§ÇÑ Ã·´Ü Á¦Á¶ ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ÁÖ¸ñÇÒ ¸¸ÇÑ µ¿ÇâÀº Á¦Á¶ °øÁ¤ÀÇ ÀÚµ¿È­ ¹× µðÁöÅÐÈ­·ÎÀÇ ÀüȯÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº Á¦Á¶ ºñ¿ëÀ» Àý°¨Çϰí Á¤È®µµ¸¦ Çâ»ó½ÃÄ×½À´Ï´Ù. ½ÃÀåÀº ¶ÇÇÑ ¿¬±¸°³¹ßÀ» °¡¼ÓÈ­Çϱâ À§ÇØ »ý¸í°øÇÐ ±â¾÷°ú Çаè¿ÍÀÇ Çù·ÂÀÌ È°¹ßÈ÷ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ÀÚ±Ý Áö¿ø°ú À¯¸®ÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¸¦ ÅëÇÑ Á¤ºÎÀÇ Áö¿øÀº ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸ÂÃãÇü ÀÇ·á°¡ °­Á¶µÇ°í ÀÖ´Â °¡¿îµ¥, mRNA ±â¼úÀº ¸ÂÃãÇü Ä¡·á¹ý °³¹ß¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °³º°È­ ¼Ö·ç¼Ç¿¡ ´ëÇÑ °ü½ÉÀº mRNA ÇÕ¼ºÀÇ ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿Çâ°ú ÃËÁø¿äÀÎÀÌ ÁøÈ­ÇÏ´Â ÇコÄÉ¾î ´ÏÁî¿Í ±â¼ú ¹ßÀü°ú ¸Â¹°¸®¸é¼­ ½ÃÀåÀº Áö¼ÓÀûÀÎ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¾ïÁ¦¿äÀΰú °úÁ¦:

mRNA ÇÕ¼º ¹× Á¦Á¶ ½ÃÀåÀº ¸î °¡Áö Áß¿äÇÑ ¾ïÁ¦¿äÀΰú ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÁÖ¿ä °úÁ¦´Â ÷´Ü ±â¼ú°ú Àü¹® Áö½ÄÀ» ÇÊ¿ä·Î ÇÏ´Â Á¦Á¶ °øÁ¤ÀÇ º¹À⼺ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ º¹À⼺Àº Á¾Á¾ Á¦Á¶ ºñ¿ëÀÇ »ó½ÂÀ¸·Î À̾îÁ® mRNA ±â¹Ý Á¦Ç°ÀÇ È®À强°ú °æÁ¦¼ºÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ À庮µµ Å« °úÁ¦ÀÔ´Ï´Ù. ¾ö°ÝÇÑ ±ÔÁ¦ »óȲÀ» ±Øº¹Çϱâ À§Çؼ­´Â ¸¹Àº ½Ã°£°ú ÀÚ¿øÀÌ ÇÊ¿äÇϸç, Á¦Ç° °³¹ß ¹× ½ÃÀå °³¹ßÀÌ ´Ê¾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿ø·á °ø±Þ¸ÁÀº ²÷¾îÁö±â ½¬¿ö mRNA Ä¡·áÁ¦ÀÇ Àû½Ã »ý»ê ¹× À¯Åë¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ÁöÀûÀç»ê±Ç ¹®Á¦µµ Á¡Á¡ ´õ º¹ÀâÇØÁö°í ÀÖ½À´Ï´Ù. ½ÃÀå °æÀïÀÇ Æ¯¼º»ó ƯÇã ºÐÀïÀÌ ºó¹øÇÏ°Ô ¹ß»ýÇÏ¿© ±â¼ú Çõ½Å°ú °øµ¿¿¬±¸¸¦ ÀúÇØÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ mRNA Á¦Ç°ÀÇ ÄݵåüÀÎ ¹°·ù°¡ ÇÊ¿äÇϹǷΠ¿î¿µºñ¿ëÀÌ »ó½ÂÇϰí, ÀÎÇÁ¶ó°¡ ºÎÁ·ÇÑ Áö¿ª¿¡¼­´Â À¯ÅëÀÌ Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î mRNA ±â¼ú¿¡ ´ëÇÑ ´ëÁßÀÇ ÀνÄÀ̳ª À߸øµÈ Á¤º¸´Â ½ÃÀå ¼ö¿ë°ú ¼ö¿ä¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ±â¾÷

BioNTech, Moderna, CureVac, Translate Bio, Arcturus Therapeutics, Sangamo Therapeutics, eTheRNA Immunotherapies, Ethris, TriLink BioTechnologies, Aldevron, Ginkgo Bioworks, Senti Biosciences, Nutcracker Therapeutics, GreenLight Biosciences, Acuitas Therapeutics

¸ñÂ÷

Á¦1Àå mRNA ÇÕ¼º¡¤Á¦Á¶ ½ÃÀå °³¿ä

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå¿¡ °üÇÑ ÁÖ¿ä ÀλçÀÌÆ®

Á¦4Àå mRNA ÇÕ¼º¡¤Á¦Á¶ ½ÃÀå Àü¸Á

Á¦5Àå mRNA ÇÕ¼º¡¤Á¦Á¶ ½ÃÀå Àü·«

Á¦6Àå mRNA ÇÕ¼º¡¤Á¦Á¶ ½ÃÀå ±Ô¸ð

Á¦7Àå mRNA ÇÕ¼º¡¤Á¦Á¶ ½ÃÀå : À¯Çüº°

Á¦8Àå mRNA ÇÕ¼º¡¤Á¦Á¶ ½ÃÀå : Á¦Ç°º°

Á¦9Àå mRNA ÇÕ¼º¡¤Á¦Á¶ ½ÃÀå : ¼­ºñ½ºº°

Á¦10Àå mRNA ÇÕ¼º¡¤Á¦Á¶ ½ÃÀå : ±â¼úº°

Á¦11Àå mRNA ÇÕ¼º¡¤Á¦Á¶ ½ÃÀå : ¿ëµµº°

Á¦12Àå mRNA ÇÕ¼º¡¤Á¦Á¶ ½ÃÀå : ÇÁ·Î¼¼½ºº°

Á¦13Àå mRNA ÇÕ¼º¡¤Á¦Á¶ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦14Àå mRNA ÇÕ¼º¡¤Á¦Á¶ ½ÃÀå : ÄÄÆ÷³ÍÆ®º°

Á¦15Àå mRNA ÇÕ¼º¡¤Á¦Á¶ ½ÃÀå : ½ºÅ×ÀÌÁöº°

Á¦16Àå mRNA ÇÕ¼º¡¤Á¦Á¶ ½ÃÀå : Áö¿ªº°

Á¦17Àå °æÀï ±¸µµ

Á¦18Àå ±â¾÷ °³¿ä

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

mRNA Synthesis and Manufacturing Market is anticipated to expand from $1.4 billion in 2024 to $8.2 billion by 2034, growing at a CAGR of approximately 19.3%. The mRNA Synthesis and Manufacturing Market encompasses the production of messenger RNA for therapeutic and vaccine applications. This market is driven by advancements in biotechnology, enabling rapid development and scalability of mRNA-based solutions. Key areas include synthesis technologies, purification processes, and quality control to ensure efficacy and safety. The rise in personalized medicine and infectious disease response is propelling market growth, with significant investments in research and infrastructure.

The mRNA Synthesis and Manufacturing Market is experiencing robust growth, spurred by advancements in biotechnology and increasing demand for personalized medicine. Within the market, the synthesis segment is leading, driven by the need for efficient and scalable production methods. The synthesis of modified nucleotides is particularly noteworthy, given its role in enhancing mRNA stability and translation efficiency. The manufacturing segment is not far behind, with contract manufacturing organizations (CMOs) gaining prominence due to their ability to offer specialized services and expertise. The vaccine development sub-segment stands out as a top performer, propelled by the success of mRNA vaccines in combating infectious diseases. Therapeutics, especially in oncology and rare diseases, represent the second highest performing sub-segment, reflecting a shift towards targeted treatments. Innovations in lipid nanoparticle delivery systems are also contributing to the market's expansion, as they improve the delivery and efficacy of mRNA-based therapies.

Market Segmentation
TypeIn vitro Transcription mRNA, Modified mRNA, Unmodified mRNA, Self-amplifying mRNA
ProductmRNA Constructs, mRNA Vaccines, mRNA Therapeutics, mRNA Delivery Systems
ServicesCustom mRNA Synthesis, mRNA Optimization, Analytical Services, Quality Control, Regulatory Support
TechnologyCell-free Systems, Enzymatic Synthesis, Chemical Synthesis, Microfluidic Systems
ApplicationInfectious Diseases, Cancer Treatment, Genetic Disorders, Cardiovascular Diseases, Rare Diseases
ProcessUpstream Processing, Downstream Processing, Formulation, Fill and Finish
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, Contract Manufacturing Organizations
ComponentNucleotides, Enzymes, Buffers, Reagents
StagePreclinical, Clinical, Commercial

Market Snapshot:

The mRNA Synthesis and Manufacturing Market is experiencing dynamic shifts in market share, pricing strategies, and product innovations. Established companies are focusing on competitive pricing to enhance market penetration, while new entrants are launching innovative products to capture emerging opportunities. The market is witnessing a robust pipeline of products, with a strong emphasis on therapeutic applications. North America dominates the landscape, driven by technological advancements and increased R&D investments. Meanwhile, the Asia-Pacific region is gaining momentum, fueled by strategic collaborations and expanding infrastructure. The competitive landscape is characterized by key players such as Moderna, BioNTech, and CureVac, who are setting industry benchmarks through strategic alliances and technological prowess. Regulatory frameworks in North America and Europe are pivotal, influencing market dynamics and compliance standards. The market is poised for growth, driven by advancements in synthetic biology and personalized medicine. However, challenges like regulatory hurdles and high production costs persist. Nonetheless, the ongoing innovation and strategic partnerships present lucrative opportunities for stakeholders.

Geographical Overview:

The mRNA synthesis and manufacturing market is witnessing robust growth across several regions, each presenting unique opportunities. North America is at the forefront, propelled by significant advancements in biotechnology and substantial investments in research and development. The presence of key industry players and a supportive regulatory framework further enhances the market's potential. Europe follows closely, with a strong focus on innovation and sustainable healthcare solutions. Government initiatives and funding for biopharmaceutical research are catalyzing market expansion. The region's commitment to cutting-edge medical research is fostering a conducive environment for mRNA technologies. In the Asia Pacific, the market is expanding rapidly, driven by technological advancements and increasing healthcare demands. Countries like China and India are emerging as pivotal growth pockets due to their vast population bases and growing investments in biotechnology. Latin America and the Middle East & Africa are also showing promising potential, with rising awareness and investments in mRNA technologies fueling market growth.

Key Trends and Drivers:

The mRNA synthesis and manufacturing market is experiencing robust growth due to several key trends and drivers. The increasing demand for mRNA-based vaccines and therapeutics is a primary driver, fueled by the success of COVID-19 vaccines. This demand is spurring investments in advanced manufacturing technologies to enhance production efficiency and scalability. A notable trend is the shift towards automated and digitalized manufacturing processes. These advancements are reducing production costs and improving precision. The market is also witnessing increased collaboration between biotech companies and academic institutions to accelerate research and development efforts. Government support through funding and favorable regulatory frameworks is further propelling market expansion. Moreover, there is a growing emphasis on personalized medicine, where mRNA technology plays a crucial role in developing tailored treatments. This focus on personalized solutions is driving innovation in mRNA synthesis. The market is poised for continued growth as these trends and drivers align with evolving healthcare needs and technological advancements.

Restraints and Challenges:

The mRNA Synthesis and Manufacturing Market faces several significant restraints and challenges. A primary challenge is the complexity of manufacturing processes, which requires advanced technology and specialized expertise. This complexity often leads to high production costs, limiting the scalability and affordability of mRNA-based products. Regulatory hurdles also pose a significant challenge. Navigating the stringent regulatory landscape requires substantial time and resources, delaying product development and market entry. Furthermore, the supply chain for raw materials is vulnerable to disruptions, impacting the timely production and distribution of mRNA therapeutics. Intellectual property issues add another layer of complexity. The competitive nature of the market leads to frequent patent disputes, hindering innovation and collaboration. Additionally, the need for cold chain logistics for mRNA products increases operational costs and limits distribution in regions with inadequate infrastructure. Lastly, public perception and misinformation about mRNA technology can affect market acceptance and demand.

Key Players:

BioNTech, Moderna, CureVac, Translate Bio, Arcturus Therapeutics, Sangamo Therapeutics, eTheRNA Immunotherapies, Ethris, TriLink BioTechnologies, Aldevron, Ginkgo Bioworks, Senti Biosciences, Nutcracker Therapeutics, GreenLight Biosciences, Acuitas Therapeutics

Research Scope:

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: mRNA Synthesis and Manufacturing Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: mRNA Synthesis and Manufacturing Market Outlook

5: mRNA Synthesis and Manufacturing Market Strategy

6: mRNA Synthesis and Manufacturing Market Size

7: mRNA Synthesis and Manufacturing Market, by Type

8: mRNA Synthesis and Manufacturing Market, by Product

9: mRNA Synthesis and Manufacturing Market, by Services

10: mRNA Synthesis and Manufacturing Market, by Technology

11: mRNA Synthesis and Manufacturing Market, by Application

12: mRNA Synthesis and Manufacturing Market, by Process

13: mRNA Synthesis and Manufacturing Market, by End User

14: mRNA Synthesis and Manufacturing Market, by Component

15: mRNA Synthesis and Manufacturing Market, by Stage

16: mRNA Synthesis and Manufacturing Market, by Region

17: Competitive Landscape

18: Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â